Insulin Pumps Gain Traction in US with Advanced Features and Growing User Base
Insulin pumps, small wearable devices delivering insulin, are gaining traction in the US. Around 350,000 people use them, predominantly those with type 1 diabetes. Let's explore these devices and their future.
Insulin pumps mimic the pancreas, delivering programmed insulin doses through a cannula under the skin. They're about the size of a deck of cards, with a display screen and insulin reservoir. They're an alternative to frequent injections and can communicate with continuous glucose monitors (CGMs) for automated insulin adjustments.
In 2025, the US market will see the t:slim X2 by Tandem, expected to integrate with Abbott's Libre 3 Plus CGM. The Mobi pump by Tandem, launched in February 2024, and the Omnipod 5 by Insulet are also notable. Innovations include automatic basal and bolus adjustments, touchscreens, waterproofing, and Bluetooth connectivity.
Insulin pumps offer convenience and automation for managing diabetes. With around 350,000 users in the US, their popularity is set to grow. Upcoming models like the t:slim X2 and Mobi pump promise enhanced features, further improving diabetes management.
Read also:
- Inadequate supply of accessible housing overlooks London's disabled community
- Strange discovery in EU: Rabbits found with unusual appendages resembling tentacles on their heads
- Duration of a Travelling Blood Clot: Time Scale Explained
- Fainting versus Seizures: Overlaps, Distinctions, and Proper Responses
